• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Comparison of Biopharmaceutical Industry between China and India 2013 Product Image

Comparison of Biopharmaceutical Industry between China and India 2013

  • ID: 2519029
  • March 2013
  • Region: China, India
  • 215 Pages
  • JZMed Inc

It has been widely recognized that biopharmaceuticals have become not only a new class of therapeutics for those diseases previously treated with small molecule drugs but also a type of innovative treatment for those previously untreatable diseases. The fast growth of the global biopharmaceutical market has prompted all global major pharma companies to increase their investment in biopharmaceuticals, which has resulted in a dramatic change in their R&D strategy and marketing focus. Today, biologic drugs have formally become an as equally important class of therapeutics as the traditional small molecule drugs.

The globe-wide change has also exerted positive impacts on China and India, the two most dynamic emerging markets in the world. It has not only prompted the rapid development of biopharmaceutical industry in these two countries but also fostered an environment for the fast growth of local biopharmaceutical markets.

The report, “Comparison of Biopharmaceutical Industry between China and India”, published by JZMed, Inc, a world renowned market research firm specialized in pharmaceutical and biotechnology industries, has conducted so far the most complete READ MORE >

Executive Summary

Attractions of fast growing Chinese and Indian biopharmaceutical markets
Comparison of biopharmaceutical manufacturing between China and India
Comparison of biopharmaceutical R&D between China and India
Outlook of future growth potentials of biopharmaceutical industry in China and India

Chapter One - Attractions of Fast Growing Chinese and Indian Biopharmaceutical Markets
Summary
Introduction
1.1 Biologic drugs have increasingly become key focus of all major pharma companies
1.2 Fast growing global biopharmaceutical market – Analysis of current global biopharmaceutical markets
1.2.1 Current total global biopharmaceutical market
1.2.2 Current global therapeutic protein market
1.2.3 Current global vaccine market
1.2.4 Current global therapeutic mAb market
1.3 Fast growing Chinese and Indian biopharmaceutical industries – Analysis of current states of biopharmaceutical industry in China and India
1.3.1 Current state and development history of Chinese biopharmaceutical industry
1.3.2 Current state and development history of Indian biopharmaceutical industry
1.4 Attraction of fast growing Chinese biopharmaceutical market – Analysis of current biopharmaceutical markets in China
1.4.1 China’s current total biopharmaceutical market
1.4.2 China’s current therapeutic protein market
1.4.3 China’s current vaccine market
1.4.4 China’s current therapeutic mAb market
1.5 Attraction of fast growing Indian biopharmaceutical market – Analysis of current biopharmaceutical markets in India
1.5.1 India’s current total biopharmaceutical market
1.5.2 India’s current therapeutic protein market
1.5.3 India’s current vaccine market
1.5.4 India’s current therapeutic mAb market

Chapter Two - Comparison of Biopharmaceutical Manufacturing between China and India
Summary
2.1 Introduction
2.2 Comparison of current general bio-manufacturing capabilities and capacities between Chinese and Indian companies
2.2.1 Classification of key steps in a bio-manufacturing process and analysis of challenges in each stage
2.2.2 Comparison of current capability of Chinese and Indian biopharma companies in cell line development
2.2.3 Comparison of current general manufacturing capabilities and capacities between Chinese and Indian biopharma companies
2.3 Comparison of biopharmaceutical products currently manufactured by Chinese and Indian companies
2.4 Comparison of current therapeutic protein manufacturing capabilities and capacities between Chinese and Indian biopharma companies
2.4.1 Comparison of types of therapeutic proteins made by Chinese and Indian biopharma companies
1. Types of therapeutic proteins made by Chinese companies
2. Types of therapeutic proteins made by Indian companies
2.4.2 Comparison of current therapeutic protein manufacturing capabilities and capacities between Chinese and Indian biopharma companies
1. Current therapeutic protein manufacturing capabilities and capacities of Chinese companies
2. Current therapeutic protein manufacturing capabilities and capacities of Indian companies
2.5 Comparison of current vaccine manufacturing capabilities and capacities between Chinese and Indian biopharma companies
2.5.1 Comparison of types of vaccines made by Chinese and Indian biopharma companies
1. Types of vaccines made by Chinese companies
2. Types of vaccines made by Indian companies
2.5.2 Comparison of current vaccine manufacturing capabilities and capacities between Chinese and Indian biopharma companies
1. Current vaccine manufacturing capabilities and capacities of Chinese companies
2. Current vaccine manufacturing capabilities and capacities of Indian companies
2.6 Comparison of current therapeutic mAb manufacturing capabilities and capacities between Chinese and Indian biopharma companies
2.6.1 Comparison of types of therapeutic mAbs manufactured by Chinese and Indian biopharma companies
1. Types of therapeutic mAbs manufactured by Chinese companies
2. Types of therapeutic mAbs manufactured by Indian companies
2.6.2 Comparison of current manufacturing capabilities and capacities of therapeutic mAbs between Chinese and Indian biopharma companies
1. Current capabilities and capacities of Chinese biopharma companies in mAb drug manufacturing
2. Current capabilities and capacities of Indian biopharma companies in mAb drug manufacturing

Chapter Three - Comparison of Biopharmaceutical R&D between China and India
Summary
3.1 Introduction
3.2 Comparison of current overall state of drug R&D between China and India
3.2.1 Current overall state of drug R&D in China
1. Short history and current state of drug R&D in China
2. Chinese government’s support and investment in drug R&D
3. Increasing private funding opportunities for drug R&D in China
4. Examples of major Chinese companies focusing on biologic drug R&D
3.2.2 Current overall state of drug R&D in India
1. Growth history and current state of drug R&D in India
2. Indian government support and investment in drug R&D
3. Private funding sources for drug R&D in India
4. Examples of major Indian companies focusing on biologic drug R&D
3.3 Comparison of current mAb drug R&D states and capabilities between Chinese and Indian biopharma companies
3.3.1 Current mAb drug R&D state and capabilities of Chinese biopharma companies
3.3.2 Current mAb drug R&D state and capabilities of Indian biopharma companies
3.4 Comparison of current vaccine R&D capabilities between Chinese and Indian biopharma companies
3.4.1 Current vaccine R&D capabilities of Chinese biopharma companies
3.4.2 Current vaccine R&D capabilities of Indian biopharma companies
3.5 Comparison of current biosimilar R&D capabilities between Chinese and Indian biopharma companies
3.5.1 Current biosimilar R&D capabilities of Chinese biopharma companies
3.5.2 Current biosimilar R&D capabilities of Indian biopharma companies

Chapter Four - Outlook of Future Growth Potentials of Biopharmaceutical Industry in China and India
Summary
4.1 Introduction
4.2 Global major pharma and biopharma companies focusing on Chinese and Indian biopharmaceutical markets
4.2.1 Major pharma and biopharma companies focusing on Chinese biopharmaceutical market
4.2.2 Major pharma and biopharma companies focusing on Indian biopharmaceutical market
4.3 Analysis of opportunities of Chinese and Indian biopharma companies in global vaccine market
4.3.1 Analysis of China’s opportunities in global vaccine market
4.3.2 Analysis of India’s opportunities in global vaccine market
4.4 Analysis of Chinese and Indian biopharma companies’ opportunities in global mAb drug market
4.5 Analysis of opportunities of Chinese and Indian biopharma companies in global biosimilar market
4.5.1 Outlook of global biosimilar market
1. Current global biosimilar market and its future growth potentials
2. Current global biosimilar regulatory status
3. Challenges of developing biosimilars
4.5.2 Analysis of China’s opportunities in global biosimilar market
4.5.3 Analysis of India’s opportunities in global biosimilar market
4.6 Chinese and Indian governments’ determination to develop biopharmaceutical industry in their countries
4.6.1 Chinese government’s determination to develop biopharmaceutical industry in China
4.6.2 Indian government’s determination to develop biopharmaceutical industry in India
4.7 Analysis of future growth hurdles facing Chinese and Indian biopharmaceutical industries
4.7.1 Chinese and Indian biopharma companies facing strong competitions in biosimilar market from biopharma companies of their neighboring Asian countries
4.7.2 Analysis of shortcomings of Chinese and Indian biopharma companies in biologic drug R&D and manufacturing
1. Analysis of shortcomings of Chinese biopharma companies in biologic drug R&D and manufacturing
2. Analysis of future growth hurdles of Indian biopharmaceutical market
4.8 Analysis of future growth potentials of Chinese and Indian biopharmaceutical markets – Market growth forecasts
4.8.1 Growth forecasts of overall biopharmaceutical markets in China and India
1. Forecast of future growth potentials of Chinese biopharmaceutical market
2. Forecast of Future growth potentials of Indian biopharmaceutical market
4.8.2 Growth forecasts of vaccine markets in China and India
1. Forecast of future growth potentials of Chinese vaccine market
2. Forecast of future growth potentials of Indian vaccine market
3. Forecasted shares of Chinese and Indian vaccine markets in future global vaccine market
4.8.3 Growth forecasts of therapeutic protein markets in China and India
1. Forecast of future growth potentials of Chinese therapeutic protein market
2. Forecast of future growth potentials of Indian therapeutic protein market
3. Forecasted shares of Chinese and Indian therapeutic protein markets in total future global therapeutic protein market
4.8.4 Growth forecasts of therapeutic mAb markets in China and India
1. Forecast of future growth potentials of therapeutic mAb market in China
2. Forecast of future growth potentials of therapeutic mAb market in India
3. Forecasted shares of Chinese and Indian therapeutic mAb markets in future global mAb drug market

Index

Index I. Chinese Companies Cited in the Report

Index II. Indian Companies Cited in the Report

Appendix

Appendix I. Research Methodology

Appendix II. About JZMed, Inc.

List of Tables

Table 1. New development trends of global biopharmaceutical industry
Table 2. Recent acquisitions of biopharma companies by major pharma companies
Table 3. Classifications of therapeutic biologic products
Table 4. Current market value and growth history of total global biopharmaceutical products
Table 5. Current market value and past growth history of global therapeutic proteins
Table 6. Current global vaccine market and its past growth history
Table 7. Current market value and growth history of global therapeutic mAbs
Table 8. Unique advantages (resources) China and India currently possess over other emerging countries
Table 9. Current structural composition of Chinese biotech industry
Table 10. Growth history of total output of Chinese biotechnology industry
Table 11. Current structural composition of Indian biotech industry
Table 12. Growth history of total output of Indian biotechnology industry
Table 13. Current state of Indian biotechnology industry
Table 14. Current Chinese biopharmaceutical market and its growth history
Table 15. Current market value and growth history of therapeutic proteins in China
Table 16. Current market value and growth history of vaccines in China
Table 17. Current market value and growth history of therapeutic mAbs in China
Table 18. Current value and growth history of Indian biopharmaceutical market and comparison with its Chinese counterpart
Table 19. Current market value and growth history of therapeutic proteins in India
Table 20. Current market value and growth history of vaccines in India
Table 21. Current market value and growth history of therapeutic mAbs in India
Table 22. Unit operations in a bio-manufacturing process
Table 23. Cell line expression systems
Table 24. Comparison of cell line development capabilities between major Chinese biopharma companies and major Indian biopharma companies
Table 25. Comparison of general manufacturing capabilities between Chinese and Indian biopharma industry
Table 26. Comparison of general manufacturing capacities between Chinese and Indian biopharma industries
Table 27. Comparison of types of biopharmaceutical products manufactured by domestic companies in China and India
Table 28. Types of therapeutic proteins made by Chinese biopharma companies
Table 29. List of recombinant interferons and their Chinese manufacturers
Table 30. List of recombinant interleukins and their Chinese manufacturers
Table 31. List of recombinant growth factors and their Chinese manufacturers
Table 32. List of major Chinese erythropoietin (EPO) manufacturers
Table 33. Major Chinese biopharma companies manufacturing insulin and analogs
Table 34. Types of therapeutic proteins made by Indian biopharma companies
Table 35. Comparison of therapeutic proteins between China and India
Table 36. List of major Indian biopharma companies manufacturing therapeutic proteins and their products
Table 37. List of major Indian insulin makers and their insulin products
Table 38. Major therapeutic protein manufacturers in China and their current capabilities
Table 39. Examples of manufacturing methods of therapeutic proteins by major Indian biopharma companies
Table 40. Major therapeutic protein producers in India and their current manufacturing capabilities and capacities
Table 41. Comparison of current therapeutic protein manufacturing capabilities between China and India
Table 42. Major Chinese vaccine makers and their vaccine products
Table 43. Major Indian vaccine makers and their vaccine products
Table 44. Comparison of types of vaccines made by domestic biopharma companies in China and India
Table 45. Current vaccine production methods widely employed in world vaccine industry
Table 46. Vaccine manufacturing capabilities of major Chinese biopharma companies
Table 47. Major Indian vaccine producers and their production capabilities and capacities
Table 48. Comparison of current vaccine manufacturing capabilities and capacities between China and India
Table 49. Marketed therapeutic mAbs and their Chinese manufacturers
Table 50. Major Indian mAb drug makers and their mAb products
Table 51. Comparison of types of therapeutic mAbs manufactured by Chinese companies and Indian companies
Table 52. Major Chinese biopharma companies manufacturing therapeutic mAbs and their capabilities
Table 53. Major Indian therapeutic mAb manufacturers and their current capabilities and capacities
Table 54. Comparison of current therapeutic mAb manufacturing capabilities and capacities between China and India
Table 55. Barriers retarding Chinese and Indian biopharma companies to gain capability in developing therapeutic mAbs
Table 56. R&D strategies currently practiced by Chinese biotech companies
Table 57. Analysis of licensing deals between multinational drug companies and Chinese companies
Table 58. Major pharma companies having corporate venture investment offices in China
Table 59. Growth trend of VC investments in Chinese life science industries
Table 60. Private funding sources for innovative drug R&D in China
Table 61. Comparison of government investment in innovative drug R&D between China and India
Table 62. Current key forces in India’s innovative drug R&D efforts and comparisons with their Chinese counterparts
Table 63. Comparison of current state of innovative drug R&D between China and India
Table 64. Novel mAb drug candidates currently under development through partnership between Chinese companies and multinational companies
Table 65. New therapeutic mAbs currently under development independently by Chinese companies/research institutions
Table 66. Novel mAb drugs under development in Indian biopharma companies
Table 67. New vaccines currently under development in China
Table 68. New vaccines currently under development in India
Table 69. Biosimilar therapeutic proteins currently under development in China
Table 70. New therapeutic proteins currently under development in China
Table 71. List of biosimilar mAbs currently under development in China
Table 72. Biosimilar therapeutic proteins currently under development in India
Table 73. Biosimilar mAbs currently under development in India
Table 74. Current distributions of global biosimilar market
Table 75. Current states of global biosimilar regulations
Table 76. Timelines of regulatory guidelines approved for biosimilars in countries around the world
Table 77. FDA’s requirements for biosimilar marketing approval in the US
Table 78. Technical challenges of developing biosimilars
Table 79. Financial challenges of developing biosimilars
Table 80. Major pharma/biopharma companies having biosimilar programs
Table 81. Current focuses of Chinese government to promote the development of Chinese biopharmaceutical industry
Table 82. Main recent initiatives of Indian government to promote Indian biopharmaceutical industry
Table 83. Current shortcomings of Chinese biopharma industry
Table 84. Major challenges facing Indian biopharmaceutical industry and market
Table 85. Future growth drivers of Chinese and Indian biopharmaceutical industries
Table 86. Forecasted future growth of Chinese biopharmaceutical market
Table 87. Forecasted future growth of Indian biopharmaceutical market and comparison with forecasted Chinese biopharmaceutical market
Table 88. Forecasted future growth of Chinese vaccine market
Table 89. Forecasted future growth of Indian vaccine market and comparison with forecasted Chinese vaccine market
Table 90. Future growth drivers of global vaccine market
Table 91. Forecasted future growth of global vaccine market
Table 92. Forecasted future growth of Chinese therapeutic protein market
Table 93. Forecasted future growth of Indian therapeutic protein market and comparison with forecasted Chinese therapeutic protein market
Table 94. Forecasted future growth of global therapeutic protein market
Table 95. Forecasted future growth of Chinese therapeutic mAb market
Table 96. Forecasted future growth of Indian therapeutic mAb market and comparison with forecasted Chinese therapeutic mAb market
Table 97. Forecasted future growth of global therapeutic mAb market

List of Figures

Figure 1. FDA approval rate of biologic drugs in recent eight years
Figure 2. Growth trend of total global biopharmaceutical market in past six years
Figure 3. Growth trend of global therapeutic protein market in past six years
Figure 4. Growth trend of global vaccine market in past six years
Figure 5. Growth trend of global therapeutic mAb market in past six years
Figure 6. Analysis of structural compositions of Chinese biotech industry
Figure 7. Growth trend of total output of Chinese biotechnology industry in past six years
Figure 8. Analysis of product compositions of Chinese biotechnology industry’s output
Figure 9. Growth trend of China-made biologic drugs marketed overseas
Figure 10. Analysis of structural compositions of Indian biotech industry
Figure 11. Growth trend of total output of Indian biotechnology industry in past six years
Figure 12. Growth trend of Chinese biopharmaceutical market in past six years
Figure 13. Growth trend of Chinese therapeutic protein market in past six years
Figure 14. Growth trend of Chinese vaccine market in past six years
Figure 15. Growth trend of Chinese therapeutic mAb market in past six years
Figure 16. Growth trend of Indian biopharmaceutical market in past six years and comparison with its Chinese counterpart
Figure 17. Growth trend of Indian therapeutic protein market in past six years
Figure 18. Growth trend of Indian vaccine market in past six years
Figure 19. Growth trend of Indian therapeutic mAb market in past six years
Figure 20. Forecasted future growth trend of Chinese biopharmaceutical market
Figure 21. Forecasted future growth trend of Indian biopharmaceutical market and comparison with its Chinese counterpart
Figure 22. Forecasted future growth trend of Chinese vaccine market
Figure 23. Forecasted future growth trend of Indian vaccine market and comparison with its Chinese counterpart
Figure 24. Forecasted future growth trend of global vaccine market
Figure 25. Forecasted future growth trend of Chinese therapeutic protein market
Figure 26. Forecasted future growth trend of Indian therapeutic protein market and comparison with its Chinese counterpart
Figure 27. Forecasted future growth trend of global therapeutic protein market
Figure 28. Forecasted future growth trend of Chinese therapeutic mAb market
Figure 29. Forecasted future growth trend of Indian therapeutic mAb market and comparison with its Chinese counterpart
Figure 30. Forecasted future growth trend of global therapeutic mAb market

List of Case Studies

Case Study 1. Pfizer’s new R&D strategy focusing on biologic drugs
Case Study 2. Roche’s new R&D strategy focusing on both small molecule drugs and biologics
Case Study 3. Examples of current manufacturing capability and capacity of one of major Indian biopharma companies
Case Study 4. China Biologic Products
Case Study 5. Indian biopharma companies building manufacturing plants dedicated to multinational company’s recombinant proteins
Case Study 6. Major biopharma company building bio-manufacturing facility in India
Case Study 7. Chinese biopharma companies developing and manufacturing HEV vaccine
Case Study 8. Major Indian vaccine makers and their capabilities
Case Study 9. Indian companies able to manufacturing antibody-drug conjugates
Case Study 10. Major pharma companies licensing drug candidates to Chinese drug companies for co-development in China
Case Study 11. More examples of recent licensing/co-development deals between multinational drug companies and Chinese companies
Case Study 12. Increasing VC investments in R&D-focused Chinese drug companies
Case Study 13. Examples of VC investment in Chinese biopharma companies
Case Study 14. Growing abundance of local venture funding opportunities for Chinese biotech companies focusing on innovative drug R&D
Case Study 15. R&D development path of Dr. Reddy’s Lab
Case Study 16. US-based biotech companies out-licensing innovative mAb drug candidates to Chinese companies
Case Study 17. Current novel mAb drug R&D programs of Shanghai CP Guojian Pharmaceutical
Case Study 18. Growing numbers of Chinese companies involved in mAb drug development
Case Study 19. Multinational biotech companies conducting mAb drug R&D in China
Case Study 20. Current mAb drug R&D activities of major Indian biopharma companies
Case Study 21. Collaborations of Chinese vaccine makers with multinational counterparts
Case Study 22. Multinational companies collaborating with Indian companies on vaccine development and commercialization
Case Study 23. Biosimilar products of 3SBio
Case Study 24. Multinational biopharma companies developing biosimilars in China
Case Study 25. Biosimilar products developed by Dr. Reddy’s Lab
Case Study 26. Major Indian biopharma companies focusing on biosimilar development and their pipelines
Case Study 27. Merck Serono forging partnership with Dr. Reddy's Lab to co-develop and market biosimilar mAbs in global market
Case Study 28. Multinational companies building mAb manufacturing facility in China
Case Study 29. Collaboration between Chinese biopharma companies and Indian counterparts in developing biosimilar mAbs
Case Study 30. Examples of blockbuster mAb drugs losing or expected to come off patent protection
Case Study 31. Multinational biopharma companies building bio-manufacturing facilities in China
Case Study 32. Key competitors of Chinese and Indian biopharma companies in Asian biosimilar market
Case Study 33. Major pharma companies encountering difficulty to protect their innovative products in Indian market
Case Study 34. IAVI partnering with Indian government institute for a broad-spectrum HIV vaccine

Note: Product cover images may vary from those shown

ALSO AVAILABLE

RELATED PRODUCTS

Our Clients

Our clients' logos